Oruka Therapeutics, Inc.
- ORKA
- NASDAQ
- Biotechnology
- Monoclonal Antibody Therapy
- Immunology/Inflammation
$74.48
Today +3.55%Quote Oct 19, 2026, 08:00 PM UTC
−26.40%over the last month
Max drawdown −26.4%From 1-month high −26.4%3 months −21.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Oruka Therapeutics
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
68
Market value
$4.93B
Quote Oct 19
Floor
$71.66
3.8% below price
Resistance
$76.88
3.2% above price
Price vs analyst targets
9 analysts
Lowest target
$120.00Highest target
$200.00
$120.00Highest target
$200.00
- Price $74.48
- Average target $144.56
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 94% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ORKAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free